Resources

These study results are consistent with Medisafe’s previously announced findings that its users are 86% adherent to their medication regimens, versus the WHO’s estimate of 50 percent for the nation as a whole.

Medisafe was the highest-scoring app of the 10 apps assessed using MARS and had the highest scores in engagement and aesthetics. It was found to be interesting, entertaining, highly interactive, and customizable. Medisafe was the only app rated as having some evidence supporting its effectiveness in nonrandomized studies.

The study focused on three areas; innovation, evidence, and adoption. IQVIA found that there are over 200 health apps introduced every day. While the majority of apps are focused on general wellness, 40% focus on managing specific conditions and that number is growing.

Results showed that existing patients who joined the Medisafe program saw a 7% increase in adherence pre- vs. post-Medisafe start compared to those not on Medisafe, who showed no statistically significant increase over the same time frame.

Medisafe is a leading cloud-based mHealth platform for medication management, helping users worldwide adhere to even the most complicated medication schedules.

The rising cost of insulin is receiving more attention in the media and medical literature with the American Diabetes Association calling for solutions to insulin affordability. Medisafe data, however, indicate that cost may not be the highest concern for many insulin patients.

Medisafe data shows that more than 25% of patients who take a leading asthma medication do so in the morning. Guidelines from the National Asthma Education and Prevention Program (NAEPP) state that this medication should only be taken at night for maximum efficacy.

This app led to a significant improvement in medication adherence for participants. 93% of patients reported that the app’s medication reminders helped them take their medications on time, a crucial factor in managing chronic conditions like hypertension, diabetes, and heart disease.

Medisafe’s real-world data shows patients treated for depression with a newer antidepressant brand (Brand-SSRI) are experiencing dramatically different perceived results in the first two months of therapy compared to patients on other SSRIs.

Medisafe’s real-world data shows that more than half of patients taking the most-prescribed antiplatelet meds have missed 1 to 5+ consecutive doses, leaving some untreated and at a greater risk of thrombosis and other complications.